AI Summary
Summary: The EU safety assessor rejected new drugs for ALS, age-related macular degeneration, and Duchenne muscular dystrophy due to insufficient evidence.
Drugs for ALS, age-related macular degeneration, and Duchenne muscular dystrophy did not get the green light due to lack of evidence.
Medscape Medical News